Friday, 19 Jul 2019

You are here

RheumNow Weekly Podcast – 3 Wiseguy Rheumatologists (11.9.18)

Dr Jack Cush reviews the News and Journal reports from the past week on RheumNow.com.  Be sure to check out our upcoming meeting in March 2019 - RheumNow Live.

  1. What works in Dactylitis? Literature review suggests ustekinumab, ixekizumab, adalimumab, and apremilast are efficient. Secukinumab, clazakizumab, abatacept, and tofacitinib were promising. Brodalumab was ineffective https://t.co/SLPcjBaNAv
  2. Analysis of Natl Inpatient Sample database (1998-2014) compared outcomes in 87605 SLE pregnancies vs matched cohort: found SLE had more C-section, IU fetal death, Pre-eclampsia, VTE, CKD, HTN, longer stays Presented by Dr. Bella Mehta #ACR18 Abst 1852 https://t.co/iYicIbOlxP
  3. Durkan Test for CTS is when the Examiner presses the thumbs over carpal tunnel and holds pressure for 30 seconds. The onset of pain or paresthesia in the median nerve distribution within 30 seconds is a positive result . https://t.co/1wlJWzX68H
  4. Study of 512 pts shows when testing for Carpal Tunnel syndrome Thenar atrophy & sensory loss were highly specific, but thenar atrophy had lowest sensitivity (22%) & Durkan test highest (96%). Tinel had lowest specificity 40.9% and NPV 59.1%. https://t.co/Wi8qxNSxIg
  5. Korean claims data analysis shows intestinal Behcets disease is associated with a 24-34 fold increased risk of hematologic malignancy (esp leukemia, myelodysplasia) vs population. BD Women not men) have an overall higher cancer risk (SIR 4.27) https://t.co/Ik6KdEGz7u
  6. JAMA Metanalysis shows there is limited evidence showing the benefit of reduced dietary salt intake in heart failure patients. https://t.co/EsxApEUsbe
  7. DEA report says 2017 was a record year for Opioid Overdose deaths - 72,000 or ~ 200 deaths per day; lead by Heroin, fentanyl, other opioids, methamphetamine and cocaine. https://t.co/jfayrQbt5d
  8. Should Immunoglobulins be Monitored with Rituximab Use   
  9. Low Short-Term Risks of NSAIDs in High Risk Patients  
  10. Controversial New Super Opioid Approved by FDA  
  11. Frankincense is derived from Boswellia plants. Boswellia serrata is an Ayurvedic purported to be anti-inflammatory; inhibits 5-lipoxygenase & possibly prostaglandins, Pilot studies in OA have shown significant pain relief and improved physical function https://t.co/OPxal73aIF
  12. Do you know who patients perceive to be a "great doctor"? Just listen - it’s always someone who shows they care and/or someone with a personality. Dispassionate, know-it-all service isn’t well received!

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

RheumNow Podcast – Don’t Take My Advice (7.19.19)

Dr. Jack Cush reports the news and new journal articles from the past week on RheumNow.com.

RheumNow Podcast – Boiling Hot MAS (7.12.19)

Dr. Jack Cush reviews this week's news and journal reports featured on RheumNow.com. PsA v. non-PsA pregnancies, Still's disease, lupus, nutritional supplements and dietary interventions, use of cannabis, tanezumab in OA, CBD oils and more.

Be ‘on point’: Guidelines for rheumatic complications of immunotherapy

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. At EULAR 2019, Madrid, several recommendations including RA, SLE, and Sjogren’s syndrome have been developed. Agreement for principles with respect to the treatment of immune mediated adverse events from cancer immunotherapy are lacking.

RheumNow Podcast – EULAR 2019 Streamin' - (6.14.19)

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. Dr. Jack Cush reports from Madrid on several novel presentations from EULAR 2019, including low-dose steroids in hand OA, ABA vs. ADA in double positive RA patients, psoriasis predictors of PsA, tildrakizumab and more.

EULAR 2019 – Day 3 Report

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. The third day of EULAR 2019 started with novel biologics, the efficacy of secukinumab in axial psoriatic arthritis, neurologic events with TNF inhibitors from the DANBIO database (OP0261), and neuropathy in SLE (OP0252), but above all this was a big poster day. Here are selected highlights from day 3 EULAR in Madrid.